TTK and breast carcinoma: In addition, diazoxide, a potassium channel opener [97], inhibits dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), an interleukin-1 receptor-associated kinase 1 (IRAK1), and threonine and tyrosine kinase (TTK) expression in breast cancer cell lines [98].